3,320 results match your criteria: "France DP; Erasmus University Medical Center[Affiliation]"

Acute graft-versus-host disease (aGVHD) of the lower gastrointestinal (GI) tract is a major cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab is a gut-selective anti-αβ integrin monoclonal antibody that reduces gut inflammation by inhibiting migration of GI-homing T lymphocytes. The efficacy and safety of vedolizumab added to standard GVHD prophylaxis (calcineurin inhibitor plus methotrexate/mycophenolate mofetil) was evaluated for prevention of lower-GI aGVHD after unrelated donor allo-HSCT in a randomized, double-blind, placebo-controlled phase 3 trial.

View Article and Find Full Text PDF

Spectro-temporal acoustical markers differentiate speech from song across cultures.

Nat Commun

June 2024

International Laboratory for Brain, Music and Sound Research (BRAMS), Montreal, QC, Canada.

Humans produce two forms of cognitively complex vocalizations: speech and song. It is debated whether these differ based primarily on culturally specific, learned features, or if acoustical features can reliably distinguish them. We study the spectro-temporal modulation patterns of vocalizations produced by 369 people living in 21 urban, rural, and small-scale societies across six continents.

View Article and Find Full Text PDF

Background: The relationships between spirometric assessment of lung function and symptoms (including exacerbations) in patients with asthma and/or chronic obstructive pulmonary disease (COPD) in a real-life setting are uncertain.

Objectives: To assess the relationships between baseline post-bronchodilator (post-BD) spirometry measures of lung function and symptoms and exacerbations in patients with a physician-assigned diagnosis of asthma and/or COPD.

Design: The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study.

View Article and Find Full Text PDF
Article Synopsis
  • Sjögren's disease (SjD) is an autoimmune disorder without approved therapies, and Dazodalibep (DAZ) is a promising new treatment that targets costimulatory signals in immune cells.
  • A clinical trial tested DAZ on two groups of SjD patients: one with moderate-to-severe disease and another with severe symptoms but less organ involvement, measuring changes in disease activity and patient-reported outcomes at day 169.
  • Both groups showed significant improvement with DAZ compared to placebo, and the drug was generally safe, though some common adverse events included COVID-19, headaches, and respiratory infections.
View Article and Find Full Text PDF

Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function.

Eur J Heart Fail

July 2024

Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.

Cardiovascular disease (CVD) is the leading cause of morbimortality in Europe and worldwide. CVD imposes a heterogeneous spectrum of cardiac remodelling, depending on the insult nature, that is, pressure or volume overload, ischaemia, arrhythmias, infection, pathogenic gene variant, or cardiotoxicity. Moreover, the progression of CVD-induced remodelling is influenced by sex, age, genetic background and comorbidities, impacting patients' outcomes and prognosis.

View Article and Find Full Text PDF

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

N Engl J Med

November 2024

From the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (B.A.W.), Biometrics (M.L.-Y., A.T.A., L.G.G.-O.), Surgical Oncology (W.J.H., A.M.J.K., A.C.J.A.), Head and Neck Surgery (W.M.C.K., C.L.Z.), Radiology (B.A.S.), and Molecular Oncology and Immunology (J.B.A.G.H.), Netherlands Cancer Institute, and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam (A.J.M.E.), Amsterdam, the Departments of Medical Oncology (C.U.B., J.B.A.G.H., F.M.S., E.K.) and Otorhinolaryngology Head and Neck Surgery (C.L.Z.), Leiden University Medical Center, Leiden, the Departments of Medical Oncology (K.A.T.N., R.C.S., A.A.M.V.), Surgical Oncology (D.J.G., R.C.S.), and Radiology and Nuclear Medicine (A.A.M.V.), Erasmus Medical Center, Rotterdam, the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht (S.B.V., K.P.M.S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (R.R.), the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.), the Department of Medical Oncology, Medisch Spectrum Twente, Enschede (D.P.), the Department of Medical Oncology, Maxima Medical Center, Veldhoven (G.V.), the Department of Medical Oncology, Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht (M.J.B.A.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.B.), the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen (G.A.P.H.), and Isala Oncology Center, Isala Hospital, Zwolle (J.-W.B.G.) - all in the Netherlands; the Department of Hematology and Medical Oncology, University Clinic Regensburg, Regensburg, Germany (C.U.B.); Melanoma Institute Australia (R.A.S., A.M.M., R.P.M.S., N.G.M., M.G., S.N.L., A.S., T.E.P., K.F.S., R.V.R., S.C., J.S., M.A.R., A.C.J.A., M.S.C., G.V.L.), the Faculty of Medicine and Health (R.A.S., A.M.M., R.P.M.S., N.G.M., S.N.L., A.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A., G.V.L.), and Charles Perkins Centre (R.A.S., G.V.L.), University of Sydney, the Departments of Tissue Pathology and Diagnostic Oncology (R.A.S., R.V.R.) and Melanoma and Surgical Oncology (R.P.M.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A.), Royal Prince Alfred Hospital, NSW Health Pathology (R.A.S., R.V.R.), the Departments of Medical Oncology (A.M.M., G.V.L.) and Breast and Melanoma Surgery (A.S.), Royal North Shore and Mater Hospitals, and the Department of Radiology, Mater Hospital (R.K.), Sydney, Royal Prince Alfred Hospital, Institute of Academic Surgery, Camperdown, NSW (A.C.J.A.), the Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC (D.E.G.), the Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC (L.S., S.S.), Lake Macquarie Oncology, Lake Macquarie Private Hospital, the Department of Medical Oncology, Calvary Mater Hospital, and the Department of Medicine, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (A.W.), the Department of Medical Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), the Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA (M.K.), the Department of Medical Oncology, Alfred Health, Melbourne, and the Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC (M.C.A.), and the Department of Medical Oncology, Westmead Hospital and Blacktown, Sydney (M.S.C.) - all in Australia; the Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (J.B.A.G.H.); the Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (J.P., P.R.); the Department of Medical Oncology, Centre Léon Bérard, Lyon (M.A.-A.), Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-Oncology and Clinical Investigation Center, Cancer Institute AP-HP, Nord Paris Cité, INSERM Unité 976, Saint Louis Hospital, Paris (C.L.), and the Department of Medical Oncology, Gustave Roussy and Paris-Saclay University, Villejuif (C.R.) - all in France; the Department of Surgical Oncology, Angeles Clinic and Research Institute, Los Angeles (M.B.F.); and the Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy (P.A.A.).

Article Synopsis
  • In a study comparing neoadjuvant (before surgery) and adjuvant (after surgery) immunotherapy for stage III melanoma, neoadjuvant treatment showed greater effectiveness.
  • The trial involved random assignment of 423 patients to receive either two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery, or surgery followed by 12 cycles of adjuvant nivolumab.
  • Results indicated a significantly higher 12-month event-free survival rate in the neoadjuvant group (83.7%) compared to the adjuvant group (57.2%), with neoadjuvant therapy leading to better patient outcomes and more major pathological responses despite a higher incidence of severe adverse events.
View Article and Find Full Text PDF

Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.

N Engl J Med

August 2024

From the Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, and the Endocrinology and Metabolism Section, Medicine Service, Lieutenant Colonel Charles S. Kettles Veterans Affairs Medical Center - both in Ann Arbor (R.J.A.); the Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas (O.H.); Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli, Naples (R.P.), the Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Endo-ERN Center for Rare Endocrine Conditions, Milan (G.R.), and the Department of Experimental Medicine, Sapienza University of Rome, Rome (A.M.I.) - all in Italy; the Division of Endocrinology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester (I.B.), and the Departments of Pediatrics and Experimental and Clinical Pharmacology, Divisions of Endocrinology and Genetics and Metabolism, University of Minnesota Medical School, Minneapolis (K.S.) - both in Minnesota; the Division of Pediatric Endocrinology, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh (S.F.W.); the Department of Endocrinology, Diabetology, and Nutrition, Endo-ERN Center for Rare Endocrine Conditions, Centre Hospitalier Universitaire d'Angers and Laboratoire Physiopathologie Cardiovasculaire et Mitochondriale, Université d'Angers, Angers, France (P.R.); the Departments of Endocrinology and Diabetes, University College London Hospital, London (U.S.); the Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna (F.W.K.); the Department of Molecular Medicine and Surgery, Karolinska Institutet, and the Department of Endocrinology, Karolinska University Hospital, Stockholm (H.F.); the National Institutes of Health Clinical Center and Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (D.P.M.); the Department of Endocrinology, Internal Medicine IV, Ludwig Maximilians Universität München, Munich, Germany (N.R.); Gordon Cutler Consultancy, Deltaville, VA (G.B.C.); and Neurocrine Biosciences, San Diego, CA (J.S., E.R., V.H.L., J.L.C., R.H.F.).

Background: Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH.

View Article and Find Full Text PDF

While most mammalian enhancers regulate their cognate promoters over moderate distances of tens of kilobases (kb), some enhancers act over distances in the megabase range. The sequence features enabling such extreme-distance enhancer-promoter interactions remain elusive. Here, we used enhancer replacement experiments in mice to show that short- and medium-range enhancers cannot initiate gene expression at extreme-distance range.

View Article and Find Full Text PDF

Dynamic Evolution of Infarct Volumes at MRI in Ischemic Stroke Due to Large Vessel Occlusion.

Neurology

June 2024

From the Institut de Bio-imagerie IBIO (F.M., J.D., V.D., T.T.), University Bordeaux; Neuroimagerie Diagnostique et Thérapeutique (D.P., G.M., T.C., V.D., T.T.), CHU de Bordeaux, France; Kansai Electric Power Hospital (H.F.), Osaka, Japan; Inserm CIC-IT U1433 (E.M., B.C.), CHRU Nancy; Institut de Psychiatrie et Neurosciences de Paris (IPNP) (P.S.), INSERM U1266; Département de Neurologie (P.S.), Hopital Fondation Rothschild, Paris; Institut des Maladies Neurodégénératives (V.P.), CNRS, UMR 5293, Bordeaux INP (P.C.), LABRI, CNRS, UMR5800, and Neurocentre Magendie (V.D., T.T.), INSERM U1215, Univ. Bordeaux; Service de Neurologie et Unité de Neuro Vasculaire (B.L.), Hôpital FOCH, Suresnes; Unité Neurovasculaire (J.M.O.), CHU de Toulouse; Unité Neurovasculaire (I.S.), CHU de Bordeaux; CNRS (M.T.D.S.), UMR-5293, Univ. Bordeaux; and Brain Connectivity and Behaviour Laboratory (M.T.D.S.), Paris, France.

Article Synopsis
  • The study investigates how the volume of brain infarcts progresses over time in stroke patients with large vessel occlusion, identifying different rates of growth among patients as slow, intermediate, and fast progressors.
  • Using advanced statistical methods on MRI data from a large cohort of stroke patients, researchers created models to predict clinical outcomes based on infarct growth patterns.
  • The results showed distinct patterns in infarct volume evolution, with specific brain regions affected at different rates, enabling predictions on recovery outcomes three months post-stroke.
View Article and Find Full Text PDF

Assessing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease: a European perspective.

Blood Transfus

September 2024

Joint Professional Advisory Committee of the UK Blood Transfusion and Tissue Transplantation Services (JPAC), London, United Kingdom.

Article Synopsis
  • Some countries are changing their rules about blood donation because they believe the risk of a disease called variant Creutzfeldt-Jakob disease (vCJD) has decreased since it was a big concern in the past, especially in the UK.
  • Experts held a meeting to talk about how to learn more about the disease and how to keep people safe during blood transfusions.
  • They agreed that the risk of getting vCJD from blood donors who traveled or received blood in the UK is very low now, and it's important for experts in Europe to work together to create safer guidelines for blood donation.
View Article and Find Full Text PDF

Background And Purpose: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST.

Patients/material And Methods: MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies.

Results And Interpretation: PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing.

View Article and Find Full Text PDF

Catalytic total oxidation is an effective technique for the treatment of industrial VOCs principally resulting from industrial processes using solvents and usually containing mono-aromatics (BTEX) and oxygenated compounds (acetone, ethanol, butanone). The aim of this work is to deposit gold nanoparticles on CoAl mixed oxide issued from layered double hydroxide (LDH) precursor by using the deposition precipitation (DP) method, which is applied with two modifications, labeled method (A) and method (B), in order to enhance the interaction of the HAuCl precursor with the support. Method (A) involves the hydrolysis of the HAuCl precursor after addition of the support, while in method (B), the gold precursor is hydrolyzed before adding the support.

View Article and Find Full Text PDF

Fecal Microbial Communities of Nellore and Crossbred Beef Calves Raised at Pasture.

Animals (Basel)

May 2024

Department of Biomedical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, 3200 Sicotte, St-Hyacinthe, QC J2S 2M2, Canada.

This study aimed to investigate the effect of age and genetics on the fecal microbiota of beef calves. Ten purebred Nellore () and ten crossbreed 50% Nellore-50% European breed () calves co-habiting on the same pasture paddock had fecal samples collected on days five (5 d), 14 d, 28 d, 60 d, 90 d, 180 d, 245 d (weaning) and 260 d after birth. All calves were kept with their mothers, and six Nellore dams were also sampled at weaning.

View Article and Find Full Text PDF

Three-Year Outcomes With Fractional Flow Reserve-Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial Infarction.

Circ Cardiovasc Interv

June 2024

Department of Cardiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital européen Georges Pompidou, France (E.P., D.B., N.D.).

Background: In patients with multivessel disease with successful primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction, the FLOWER-MI trial (Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction) showed that a fractional flow reserve (FFR)-guided strategy was not superior to an angiography-guided strategy for treatment of noninfarct-related artery lesions regarding the 1-year risk of death from any cause, myocardial infarction, or unplanned hospitalization leading to urgent revascularization. The extension phase of the trial was planned using the same primary outcome to determine whether a difference in outcomes would be observed with a longer follow-up.

Methods: In this multicenter trial, we randomly assigned patients with ST-segment-elevation myocardial infarction and multivessel disease with successful percutaneous coronary intervention of the infarct-related artery to receive complete revascularization guided by either FFR (n=586) or angiography (n=577).

View Article and Find Full Text PDF

Unraveling redox pathways of the disulfide bond in dimethyl disulfide: Ab initio modeling.

J Mol Model

May 2024

Physique et Chimie Théoriques, UMR 7019, Faculté des Sciences et Technologies, Université de Lorraine, BP 70239, 54506, Vandoeuvre Lès Nancy Cedex, France.

Context: In cellular environments, the reduction of disulfide bonds is pivotal for protein folding and synthesis. However, the intricate enzymatic mechanisms governing this process remain poorly understood. This study addresses this gap by investigating a disulfide bridge reduction reaction, serving as a model for comprehending electron and proton transfer in biological systems.

View Article and Find Full Text PDF

Potential of guar gum as a leaky gut model in broilers: Digestibility, performance, and microbiota responses.

Anim Nutr

June 2024

Department of R&I in Monogastric Animal Nutrition, European Laboratory of Innovation Science & Expertise (ELISE), Adisseo France S.A.S., Saint Fons, France.

Diet is a major modulator of animal resilience and its three pillars: host's immune response, gut microbiota, and intestinal barrier. In the present study, we endeavour to delineate a challenging condition aimed to degrade these pillars and elucidate its impact on broiler performance and nutrient digestibility. To attain this objective, we opted to use guar gum (GG) as a source of galactomannan.

View Article and Find Full Text PDF

Environmental impact of dietary patterns in 10 European countries; a cross-sectional analysis of nationally representative dietary surveys.

Eur J Public Health

October 2024

NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, NOVA University Lisbon, Lisbon, Portugal.

Background: Changing dietary patterns is essential to reducing the substantial environment impact of agriculture and food production systems. We performed a cross-country comparison of dietary patterns and their associated environmental impact in Europe, including by sociodemographic factors.

Methods: We analyzed pooled cross-sectional dietary records collected during 2010-18 from 10 European countries using the European Food Safety Authority (EFSA) Comprehensive European Food Database (16 508 adults; aged 18-79 years).

View Article and Find Full Text PDF

Retrotransposons are mobile DNA sequences duplicated via transcription and reverse transcription of an RNA intermediate. Cis-regulatory elements encoded by retrotransposons can also promote the transcription of adjacent genes. Somatic LINE-1 (L1) retrotransposon insertions have been detected in mammalian neurons.

View Article and Find Full Text PDF
Article Synopsis
  • Secondary tropical forests are vital for carbon storage and biodiversity, making it necessary to understand their growth patterns for effective restoration and climate change strategies.
  • The study analyzed demographic information from over 500 tree species across different stages of forest succession in various climates to determine the range of demographic strategies (growth, mortality, recruitment rates) present.
  • Findings indicate that early successional forests already exhibit the full range of demographic strategies found in old-growth forests, suggesting that known diversity from old-growth studies can apply broadly, but additional research in secondary forests is still needed.
View Article and Find Full Text PDF

This study introduces a modification to the roller compaction model proposed by Sousa et al. to account for the effect of roll speed on powder compaction in the dry granulation process. The proposed model enhances the prediction accuracy, particularly at higher roll speeds, which are often overlooked in existing models.

View Article and Find Full Text PDF

Background: Studies comparing bridging intravenous thrombolysis (IVT) with direct endovascular therapy (EVT) in patients with acute ischemic stroke who present late are limited. We aimed to compare the clinical outcomes and safety of bridging IVT in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who underwent EVT 6 to 24 hours after time last known well.

Methods: We enrolled patients with anterior circulation large vessel occlusion stroke and a National Institutes of Health Stroke Scale score of ≥6 from 20 centers across 10 countries in the multicenter retrospective CLEAR study (CT for Late Endovascular Reperfusion) between January 2014 and May 2022.

View Article and Find Full Text PDF

Background: Diffuse coronary artery disease affects the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiologic coronary artery disease patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularization and procedural outcomes.

View Article and Find Full Text PDF

Down syndrome (DS) is a genetic disease characterized by a supernumerary chromosome 21. Intellectual deficiency (ID) is one of the most prominent features of DS. Central nervous system defects lead to learning disabilities, motor and language delays, and memory impairments.

View Article and Find Full Text PDF

(1) Background: Digital pathology (DP) is transforming the landscape of clinical practice, offering a revolutionary approach to traditional pathology analysis and diagnosis. (2) Methods: This innovative technology involves the digitization of traditional glass slides which enables pathologists to access, analyze, and share high-resolution whole-slide images (WSI) of tissue specimens in a digital format. By integrating cutting-edge imaging technology with advanced software, DP promises to enhance clinical practice in numerous ways.

View Article and Find Full Text PDF